Abstracts tagged "Behcet’s syndrome"

Abstract Number: 2721 • 2017 ACR/ARHP Annual Meeting
Anti-IL6-Receptor Tocilizumab in Refractory Uveitis Associated to Extraocular Manifestations in Patients with Behçet’s Disease. Multicenter Study
Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Lucia C. Domínguez-Casas¹, Nuria Vegas-Revenga¹, Vanesa Calvo-Río¹, Natalia Palmou Fontana², Ricardo Blanco³, Javier Loricera¹, MC Gonzalez-Vela⁴, Emma Beltrán⁵, Lucía Martínez Costa⁶, Elia Valls Pascual⁶, Marisa Hernández Garfella⁵, Antonio Atanes⁷, Miguel Cordero Coma⁸, Joan Miquel Nolla Solé⁹, Carmen Carrasco Cubero¹⁰, Enar Pons¹¹ and Miguel Angel González-Gay², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁵Hospital General Universitario de Valencia, Valencia, Spain, ⁶Hospital Peset, Valencia, Spain, ⁷Hospital Universitario de A Coruña, A Coruña, Spain, ⁸Hospital de León, León, Spain, ⁹Hospital Universitari de Bellvitge, Barcelona, Spain, ¹⁰Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain
Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to extraocular manifestations due to Behçet’s disease (BD). Methods: Multicenter study of patients…
Abstract Number: 2722 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis of Behçet’s Disease. Multicenter Study of 103 Cases
Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Lucia C. Domínguez-Casas¹, Nuria Vegas-Revenga¹, Vanesa Calvo-Río¹, Emma Beltrán², Juan Sánchez-Burson³, Marina Mesquida⁴, Alfredo Adán⁴, M Victoria Hernández⁴, Javier López-Longo⁵, Marisa Hernández Garfella², Elia Valls Pascual⁶, Lucía Martínez Costa⁶, Agustí Sellas-Fernandez⁷, José L. García-Serrano⁸, José-Luis Callejas-Rubio⁸, Norberto Ortego⁸, José M. Herreras⁹, Alejandro Fonollosa¹⁰, Olga Maíz¹¹, Ana Blanco¹², Ignacio Torre¹³, C. Fernandez-Espartero¹⁴, V. Jovani¹⁵, D. Peiteado Lopez¹⁶, David Díaz Valle¹⁷, Esperanza Pato¹⁷, J. Cruz¹⁸, C. Fernandez-Cid¹⁸, Elena Aurrecoechea¹⁹, M. García²⁰, Miguel A. Caracuel²¹, Antonio Atanes²², F. Francisco²³, Santos Insúa²⁴, S. Gonzalez-Suárez²⁵, A. Sánchez-Andrade²⁶, L. Linares²⁷, F. Romero-Bueno²⁸, A. J. García²⁹, R. Almodovar³⁰, Enrique Mínguez³¹, Carmen Carrasco Cubero³², E. Raya Álvarez⁸, M. Alcalde-Villar³³, C. Fernández-Carbadillo³⁴, FA. Pagés³⁵, MC Gonzalez-Vela³⁶, Rosalia Demetrio³⁷, Enar Pons³⁷, Jose L. Hernández³⁸, Miguel Angel González-Gay³⁹ and Ricardo Blanco⁴⁰, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital General Universitario de Valencia, Valencia, Spain, ³Hospital de Valme, Sevilla, Spain, ⁴Hospital Clinic, Barcelona, Spain, ⁵Hospital Gregorio Marañón, Madrid, Spain, ⁶Hospital Peset, Valencia, Spain, ⁷Hospital Vall d´Hebron, Barcelona, Spain, ⁸Hospital San Cecilio, Granada, Spain, ⁹Hospital Universitario IOBA, Valladolid, Spain, ¹⁰Hospital de Cruces, Bilbao, Spain, ¹¹Hospital Donosti, San Sebastian, Spain, ¹²Ophthalmology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, ¹³Hospital Basurto, Bilbao, Spain, ¹⁴Hospital Universitario de Móstoles, Madrid, Spain, ¹⁵Hospital General Alicante, Alicante, Spain, ¹⁶Hospital Universitario La Paz, Madrid, Spain, ¹⁷Hospital Clínico San Carlos, Madrid, Spain, ¹⁸Hospital Pontevedra, Pontevedra, Spain, ¹⁹Hospital Sierrallana, Torrelavega, Spain, ²⁰Hospital La Princesa, Madrid, Spain, ²¹Hospital Córdoba, Córdoba, Spain, ²²Hospital Universitario de A Coruña, A Coruña, Spain, ²³Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ²⁴Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, ²⁵Hospital Cabueñes, Gijón, Spain, ²⁶Hospital Lucus Augusti, Lugo, Spain, ²⁷Hospital Arrixaca, Murcia, Spain, ²⁸Fundación Jiménez Díaz, Madrid, Spain, ²⁹Hospital 12 de Octubre, Madrid, Spain, ³⁰Hospital Universitario Fundación Alcorcón, Madrid, Spain, ³¹Hospital Clínico Zaragoza, Zaragoza, Spain, ³²Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ³³Hospital Severo Ochoa, Madrid, Spain, ³⁴Hospital General Universitario de Elda, Alicante, Spain, ³⁵Complejo Asistencial de Palencia, Palencia, Spain, ³⁶Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³⁷Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain, ³⁸Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³⁹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Johannesburg, South Africa, ⁴⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Uveitis is a severe manifestation of Behçet Disease (BD). The treatment is based on corticosteroids and conventional immunosuppressive drugs. In refractory cases, anti-TNFα had…
Abstract Number: 2723 • 2017 ACR/ARHP Annual Meeting
Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group
Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Nuria Vegas-Revenga¹, Lucia C. Domínguez-Casas¹, Vanesa Calvo-Río¹, Emma Beltrán², Juan Sánchez-Burson³, Marina Mesquida⁴, Alfredo Adán⁴, M Victoria Hernández⁴, Marisa Hernández Garfella², Elia Valls Pascual⁵, Lucía Martínez Costa⁵, Agustí Sellas-Fernandez⁶, Miguel Cordero Coma⁷, Manuel Díaz-Llopis⁸, Roberto Gallego⁸, David Salom⁸, Norberto Ortego⁹, José L. García-Serrano⁹, José-Luis Callejas-Rubio⁹, José M. Herreras¹⁰, Ángel M García-Aparicio¹¹, Olga Maíz¹², Ana Blanco¹³, Ignacio Torre¹⁴, David Díaz Valle¹⁵, Esperanza Pato¹⁵, Elena Aurrecoechea¹⁶, Miguel A. Caracuel¹⁷, Fernando Gamero¹⁸, Enrique Mínguez¹⁹, Carmen Carrasco Cubero²⁰, Alejandro Olive²¹, Julio Vázquez²², Oscar Ruiz Moreno²³, Fernando Jiménez-Zorzo²⁴, Javier Manero²⁴, Myriam Gandia Martinez²⁵, Esteban Rubio-Romero²⁶, F. Javier Toyos-Sáenz de Miera²⁷, Javier López-Longo²⁸, JM Nolla²⁹, Marcelino Revenga³⁰, Rosalia Demetrio³¹, Enar Pons³¹, Miguel Angel González-Gay¹ and Ricardo Blanco³², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital General Universitario de Valencia, Valencia, Spain, ³Hospital de Valme, Sevilla, Spain, ⁴Hospital Clinic, Barcelona, Spain, ⁵Hospital Peset, Valencia, Spain, ⁶Hospital Vall d´Hebron, Barcelona, Spain, ⁷Hospital de León, León, Spain, ⁸Hospital Universitario La Fe, Valencia, Spain, ⁹Hospital San Cecilio, Granada, Spain, ¹⁰Hospital Universitario IOBA, Valladolid, Spain, ¹¹Hospital Donosti, San Sebastián, Spain, ¹²Hospital Donosti, San Sebastian, Spain, ¹³Ophthalmology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, ¹⁴Hospital Basurto, Bilbao, Spain, ¹⁵Hospital Clínico San Carlos, Madrid, Spain, ¹⁶Hospital Sierrallana, Torrelavega, Spain, ¹⁷Hospital Córdoba, Córdoba, Spain, ¹⁸Hospital San Pedro Alcántara, Cácerer, Spain, ¹⁹Hospital Clínico Zaragoza, Zaragoza, Spain, ²⁰Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²¹Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²²Hospital de Ferrol, A Coruña, Spain, ²³Ophthalmology and Rheumatology., Ophtalmology. Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁴Hospital Miguel Servet, Zaragoza, Spain, ²⁵Hospital Puerta del Mar, Cádiz, Spain, ²⁶Hospital Universitario Virgen del Rocío, Sevilla, Spain, ²⁷Hospital Universitario Virgen Macarena, Sevilla, Spain, ²⁸Hospital Gregorio Marañón, Madrid, Spain, ²⁹Hospital Universitari de Bellvitge, Barcelona, Spain, ³⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ³¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain, ³²Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Adalimumab (ADA) therapy has been approved by the EMA and the FDA in non-infectious and non-anterior uveitis. After loading, the maintenance dose is 40…
Abstract Number: 2724 • 2017 ACR/ARHP Annual Meeting
Apremilast for Refractory Mucocutaneous Ulcers of Behçet’s Disease. National Multicenter Study of 14 Cases
Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Javier Loricera¹, Nuria Vegas-Revenga¹, Lucia C. Domínguez-Casas¹, Jose L. Hernández², Clara Moriano³, Maria Dolores García-Armario⁴, Iván Castelvi⁵, Francisca Sivera⁶, Jaime Calvo-Alen⁷, Isabel de la Morena⁸, Francisco Ortiz-Sanjuán⁹, José Andrés Román-Ivorra⁹, Ana Pérez-Gómez¹⁰, MC Gonzalez-Vela¹¹, Miguel Angel González-Gay¹ and Ricardo Blanco¹², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Hospital de Xàtiva, Xàtiva, Spain, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Hospital General Universitario de Elda, Elda, Spain, ⁷Hospital Universitario Araba, Vitoria, Spain, ⁸Hospital General Universitario de Valencia, Valencia, Spain, ⁹Hospital La Fe, Valencia, Spain, ¹⁰Hospital Príncipe de Asturias, Alcalá de Henares, Spain, ¹¹Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹²Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Behçet´s disease (BD) is characterized by recurrent oral and/or genital ulcers accompanied by ocular, cutaneous, articular, gastrointestinal, and/or neurologic manifestations. Oral and/or genital aphthous…
Abstract Number: 2728 • 2017 ACR/ARHP Annual Meeting
Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients
Pelin Ünsal¹, Pamir Cerci², Şükrü Alper Açıkgöz², Göksal Keskin² and Ümit Ölmez², ¹Ankara University School of Medicine, Ankara, Turkey, ²Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey
Background/Purpose: Behcet's disease (BD) is a systemic vasculitis disorder of unknown etiology with recurrent exacerbations and remissions. The etiopathogenesis of the disease is still unclear.…
Abstract Number: 2729 • 2017 ACR/ARHP Annual Meeting
Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome
Hasan Tuzun¹, Gul Guzelant², Ozkan Demirhan³, Buge Oz⁴, Izzet Fresko², Vedat Hamuryudan², Hasan Yazici² and Emire Seyahi², ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Cardiovascular Surgery, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul Bilim University, Medical Faculty, Department of Thoracic Surgery, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Department of Pathology, Istanbul, Turkey
Background/Purpose: The mainstay treatment of pulmonary artery involvement (PAI) in Behcet’s syndrome (BS) is immunosuppresion and corticosteroids (1). The role of surgical intervention in the…
Abstract Number: 2732 • 2017 ACR/ARHP Annual Meeting
Recommendations for the Management of Neuro-Behcet’s Disease By the Japanese National Research Committee for Behcet’s Disease
Hirotoshi Kikuchi¹, Tetsuji Sawada², Masato Okada³, Mitsuhiro Takeno⁴, Masataka Kuwana⁴, Yoshiaki Ishigatsubo⁵, Izumi Kawachi⁶, Hideki Mochizuki⁷, Susumu Kusunoki⁸ and Shunsei Hirohata⁹, ¹Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁶Department of Neurology, Niigata University Medical and Dental Hospital, Niigata, Japan, ⁷Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁸Department of Neurology, Kinki University School of Medicine, Osaka, Japan, ⁹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Central nervous system involvement is one of the most serious complications in Behçet’s disease (BD). This condition is referred to as neuro-Behçet’s disease (NB)…
Abstract Number: 2744 • 2017 ACR/ARHP Annual Meeting
Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment
Petros P Sfikakis¹, Aikaterini Arida¹, Stylianos Panopoulos², Kalliopi Fragkiadaki², George Pentazos³, Katerina Laskari³, Maria Tektonidou¹ and Nikos Markomichelakis², ¹First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, athens, Greece, ²First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, ³Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece
Background/Purpose: Anti-TNF treatment has been shown to be effective in inducing complete remission in many Behcet’s disease (BD) patients with eye, large vessel, intestine and…
Abstract Number: 108 • 2017 Pediatric Rheumatology Symposium
Characteristics and long-term outcome of children and adolescents with initial diagnosis of Behçet’s disease in a tertiary care center in Brazil
Milagro Raquel Tovar-Avila¹, Francisco Hugo Gomes², Lucenir Da Silva³, Virginia Ferriani⁴ and Luciana Carvalho², ¹Pediatric Reumatology Division, Ribeirão Preto Medical School - University of São Paulo, Rbeirão Preto, Brazil, ²Pediatric Rheumatology Division, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil, ³Rheumatology Division, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil, ⁴Pediatric Reumatology Division, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil
Background/Purpose: Behet's disease (BD) is a rare systemic inflammatory disease with nonspecific clinical presentation that can mimic infections, tumors and other diseases. Diagnostic delay of…
Abstract Number: 109 • 2017 Pediatric Rheumatology Symposium
Clinical features of pediatric Behçet’s disease patients in Japan
Ken-ichi Yamaguchi¹ and Satoshi Fujikawa², ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno－Rheumatology Center, St.luke's International Hospital, Tokyo, Japan
Background/Purpose: To diagnose pediatric patients as Behçet’s disease (BD) is challenging. Sensitivity of four BD criteria, three BD criteria made for adult patients and Paediatric…
Abstract Number: 2034 • 2016 ACR/ARHP Annual Meeting
Novel Susceptible Genes for Behçet’s Disease Identified By Dense Genotyping of Immune-Related Loci Implicate Host Responses to Microbial Exposure
Masaki Takeuchi^1,2, Nobuhisa Mizuki³, Akira Meguro⁴, Michael J. Ombrello⁵, Yohei Kirino⁶, Colleen Satorius⁷, Julie Le¹, Mary Blake⁸, Burak Erer⁹, Tatsukata Kawagoe², Duran Ustek¹⁰, Ilknur Tugal-tutkun¹¹, Emire Seyahi¹², Yilmaz Ozyazgan¹³, Inês Sousa¹⁴, Fereydoun Davatchi¹⁵, Vânia Francisco¹⁴, Farhad Shahram¹⁶, Bahar Abdollahi¹⁷, Abdolhadi Nadji¹⁷, Niloofar Shafiee¹⁷, Fahmida Ghaderibarmi¹⁸, Shigeaki Ohno¹⁹, Atsuhisa Ueda⁶, Yoshiaki Ishigatsubo²⁰, Massimo G. Gadina²¹, Sofia Oliveira¹⁴, Ahmet Gul⁹, Daniel L. Kastner¹ and Elaine F. Remmers²², ¹National Human Genome Research Institute, Bethesda, MD, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Yokohama City University, Yokohama, Japan, ⁴Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷NIAMS, N.I.H, Bethesda, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹⁰Istanbul University, Istanbul, Turkey, ¹¹Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ¹²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ¹³Ophthalmology, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ¹⁴Universidade de Lisboa, Lisboa, Portugal, ¹⁵Internal Medicine, Rheumatology Research Ctr-Tehran Univ, Tehran, Iran, ¹⁶Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), ¹⁷Tehran University of Medical Sciences, Teheran, Iran (Islamic Republic of), ¹⁸Tehran University of Medical Sciences, Teheran, Portugal, ¹⁹Hokkaido University Graduate School of Medicine, Hokkaido, Japan, ²⁰Int. Med. & Clin. Immunology, Yokohama City Grad Sch of Med, Yokohama, Japan, ²¹Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²²National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Recent genetic studies have identified multiple susceptibility loci for Behçet’s disease. However, these genetic factors do not fully explain the apparent disease heritability.The purpose…
Abstract Number: 2144 • 2016 ACR/ARHP Annual Meeting
Functional Analysis of Macrophages in BehçEt’s Disease: C-C Chemokine Receptor Type 1 (CCR1) and IL-10 Are Implicated in Pathogenesis of the Disease
Hiroto Nakano¹, Yohei Kirino¹, Momoko Ohno¹, Kana Higashitani¹, Mitsuhiro Takeno², Ryusuke Yoshimi¹ and Hideaki Nakajima³, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
Background/Purpose: The recent GWAS and subsequent studies have identified susceptible genes such as CCR1 and IL10 genes, suggesting pathological roles of macrophages in Behçet's disease…
Abstract Number: 2150 • 2016 ACR/ARHP Annual Meeting
Autoimmune Uveitis : Potential Role of Interleukin-22 (IL-22) in Pathogenesis
El-Desouki Fouda¹, El-Sayed Mostafa Elewah², Mona Elrayes³, Ghada Fouda⁴ and Mohamed Ahmed Bakry⁵, ¹Al-Azhar University, Dokki Cairo, Egypt, ²Opthalmology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt, ³Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt, ⁴Faculty of Medicine, Al-Azhar University, Cairo, Egypt, ⁵Al-Azhar University, Allergy & Immunology Center, Cairo, Egypt
Background/Purpose: : IL-22 is a member of IL-10 family, with both anti- inflammatory and pro- inflammatory functions, orchestrating the immune and inflammatory response.IL-22 is secreted…
Abstract Number: 2940 • 2016 ACR/ARHP Annual Meeting
Bechet’s Disease and Sleep Quality in Korean Patients
Chang-Nam Son¹, Ji Min Lee¹, Hye-Jin Jeong², Ji-Min Kim¹, Sang-Hyon Kim¹, Sung Soo Kim³ and Seung-Hyeon Bae⁴, ¹Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Ulsan University School of Medicine, GangNeung Asan Hospital, Gangneung, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: The purpose of this study was to find out the effects of sleep quality on Behcet’s disease in Korean population. We also investigated the…
Abstract Number: 2941 • 2016 ACR/ARHP Annual Meeting
Optimization of Adalimumab on Refractory Uveitis of Behcet’s Syndrome. Multicenter Study of 23 Patients
Carlos Fernández-Díaz¹, Ricardo Blanco¹, Vanesa Calvo-Río¹, Javier Loricera¹, J. Sanchez-bursón², Norberto Ortego Centeno³, Jose L. García Serrano⁴, Miguel Cordero⁵, J. Vazquez⁶, Emma Beltran⁷, Elia Valls⁸, O. Maiz Alonso⁹, Ana Blanco¹⁰, Ignacio Torre¹¹, Angel García-Aparicio¹², F.j Toyos-saénz¹³, L. Martinez-Costa¹⁴, Lucia C. Domínguez-Casas¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital Valme, Hospital Valme, Sevilla, Spain, ³Medicine Department, Hospital Universitario San Cecilio, Granada, Spain, ⁴Ophthalmology, Hospital Universitario San Cecilio, Granada, Spain, ⁵Ophthalmology, Hospital de León, León, Spain, ⁶Rheumatology, Hospital de Ferrol, Ferrol, Spain, ⁷Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Dr. Peset., Valencia, Spain, ⁹Rheumatology, Hospital Donostia, San Sebastian, Spain, ¹⁰Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ¹¹Rheumatology, Hospital de Basurto, Bilbao, Spain, ¹²Rheumatology, Ophthalmology and rheumatology, Hospital de Ferrol, Ferrol, Ferrol, Spain, ¹³Rheumatology,, Hospital Virgen de la Macarena, Sevilla, Spain, ¹⁴Hospital Dr. Peset., Valencia, Spain
Background/Purpose: In non-infectious no anterior uveitis, adalimumab (ADA) is the only biologic drug that has shown efficacy in phase III randomized, double blind studies,…

« Previous Page
1
…
3
4
5
6
7
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].